CAJ | 학술논문

目的：探讨卵巢癌患者血浆miRNA分子标志物水平与铂类化疗敏感性的相关性。方法应用实时定量PCR方法检测48例卵巢癌患者化疗前后血浆中miRNA的表达，13例体检正常者为内参对照，观察卵巢癌患者铂类化疗药物的疗效及预后的关系。结果初检的11种miRNA中，仅有5种miRNA（miR-124，miR-145，miR-22，miR-106a，miR-142）能够在外周血中检测出。其中3种miRNA（miR-22，miR-106a，miR-142）在正常人和卵巢癌患者的外周血中表达水平比较差异有统计学意义（ P ＜0.01）。患者化疗后外周血中仅miR-22水平显著升高（约3.2倍），且miR-22水平高者对化疗反应多数敏感，反之不敏感。患者外周血miR-22的表达水平与其预后呈正相关（ P ＜0.05）。结论血浆中miR-22，miR-106a，miR-142水平升高可能参与了卵巢癌的发生发展，化疗患者敏感者仅miR-22呈高表达，不敏感者miR-22呈低表达，提示其可作为预测化疗敏感性及预后的指标之一。
목적：탐토란소암환자혈장miRNA분자표지물수평여박류화료민감성적상관성。방법응용실시정량PCR방법검측48례란소암환자화료전후혈장중miRNA적표체，13례체검정상자위내삼대조，관찰란소암환자박류화료약물적료효급예후적관계。결과초검적11충miRNA중，부유5충miRNA（miR-124，miR-145，miR-22，miR-106a，miR-142）능구재외주혈중검측출。기중3충miRNA（miR-22，miR-106a，miR-142）재정상인화란소암환자적외주혈중표체수평비교차이유통계학의의（ P ＜0.01）。환자화료후외주혈중부miR-22수평현저승고（약3.2배），차miR-22수평고자대화료반응다수민감，반지불민감。환자외주혈miR-22적표체수평여기예후정정상관（ P ＜0.05）。결론혈장중miR-22，miR-106a，miR-142수평승고가능삼여료란소암적발생발전，화료환자민감자부miR-22정고표체，불민감자miR-22정저표체，제시기가작위예측화료민감성급예후적지표지일。
Objective To investigate the potentiality of specific miRNA level in blood plasma of ovarian cancer patients as a molecular marker to predict sensitivity and response to platinum-based chemotherapy .Methods Quantitative polymerase chain reac-tion ( Q-PCR) was used to check the changing of miRNA level in blood plasma before and after chemotherapy , and explored the rela-tivity between variation and chemotherapy response and clinic outcome .Results Among preliminary screened 11 miRNAs, only 5 miRNAs were able to be detected in peripheral blood .There existed variations in 3 miRNAs ( miR-22, miR-106a, miR-142).Further detection of the changing of miRNA level in blood plasma before and after therapy , miR-22 was found significantly up-regulated in blood plasma that was underwent platinum-based chemotherapy .Meanwhile, ovarian cancer patients with high miR-22 level were most-ly sensitive to platinum-based therapy.Otherwise, miR-22 was positive relative to the clinic prognosis of patients with ovarian cancer . Conclusions miR-22, miR-106a, and miR-142 might participate in the generation and development of ovarian cancer .miR-22 in pe-ripheral blood was probably identified as a novel molecular marker of prediction of the sensitivity to platinum in ovarian cancer patients .